Study tests if Two-Drug maintenance beats One-Drug after stem cell transplant for myeloma

NCT ID NCT05271630

Ongoing Knowledge-focused Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at 69 people with multiple myeloma who had a stem cell transplant. It compares those who take one maintenance drug versus two drugs (an immunomodulatory agent plus a proteasome inhibitor) to see which keeps the cancer away longer. The goal is to learn if the two-drug combo leads to better outcomes, like turning cancer markers from positive to negative.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Immunomodulatory agent and proteasome inhibitor
What this could lead to: If successful, this could help doctors choose the best maintenance therapy to keep multiple myeloma in remission longer after a stem cell transplant.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove one treatment is better. Results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.